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and high necessity/low concern. Non-adherence was measured
as skipping, taking smaller doses, delaying ﬁlls or stopping ﬁlls
of a medication in the past 30 days. Reasons for non-adherence
included cost, forgetting, experience with the medication, self-
assessed need, and convenience. RESULTS: A total of 4737
respondents took a prescription cholesterol-lowering medica-
tion; 28.1% reporting at least one form of non-adherence. Rates
of non-adherence varied signiﬁcantly among the four patient seg-
ments as did demographics, types of and reasons for non-
adherence. At the univariate level, results showed that beliefs,
age younger than 65, less time on medication, non-white eth-
nicity, and lower education were associated with non-adherence.
When included in the same model, the above factors, with the
exception of time on medication, remained signiﬁcantly associ-
ated with non-adherence. Even after controlling for key demo-
graphic characteristics, these patient belief groups remained
signiﬁcantly associated with non-adherence. CONCLUSION:
Beliefs about medication necessity and concerns are relevant to
medication non-adherence allowing creation of inﬂuential mes-
saging to improve adherence behavior. Understanding belief dif-
ferences has actionable implications for disease management
programs.
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OBJECTIVE: Atrial Fibrillation (AF) is a frequent arrhythmia
that has a great impact on Health-Related Quality of Life
(HRQoL). Nowadays there is no speciﬁc questionnaire in AF, for
this reason we have developed the AF-QoL questionnaire.
METHODS: In order to deﬁne the main dimensions the ques-
tionnaire should cover, a literature review and a focus group with
three cardiologists were performed. A semi-structured interview
was conducted in 17 patients with AF to evaluate the impact of
disease, symptoms and treatment on HRQoL. From the content
of the interviews a sample of items were identiﬁed. Each item
was subsequently rated by the cardiologists, according to clarity,
frequency and importance to reduce the number of items.
Remaining items were edited in a questionnaire format and
administered to a sample of 112 patients (47.3% persistent AF
and 52.7% paroxistic AF). A factor analysis and a Rasch analy-
sis were performed to obtain the ﬁnal pilot questionnaire before
the validation study. RESULTS: After qualitative reduction, a 40
items questionnaire was obtained (AF-QOL 40). Factor analysis
identiﬁed 2 dimensions with a total variance explained of 50.2%.
Rasch analysis was used to exclude those items with inadequate
adjustment (INFIT or OUTFIT >1.30 and <0.70) or redundant
with other items in the measurement scale, obtaining a total of
18 items. This ﬁnal questionnaire (AF-QOL 18) has a good inter-
nal consistency (Cronbach’s alpha =0.91). Comparative psycho-
metric performance between AF-QOL 40 and AF-QoL 18
showed similarity in internal consistency (0.95 and 0.91), item
correlation-overall score (0.4–0.76 and 0.45–0.76) and a high
correlation between the two questionnaires (r = 0.94). CON-
CLUSION: AF-QoL is a new questionnaire of 18 items, with ini-
tially good psychometric properties though validation is needed
through a formal validation process in adequate sample size.
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OBJECTIVES: Chronic patients tend to develop different thera-
peutic strategies depending on treatment efﬁcacy, and show pref-
erence for those treatments with fewer undesired effects. It is
likely that those treatments showing best patient satisfaction
should be preferred, should increase adherence and hence beneﬁt
from pharmacological therapeutic beneﬁts. The psychometric
properties of a recently developed questionnaire of Treatment
Satisfaction (SATMED-Q) are assessed in a chronic hypertensive
population. METHODS: A sample of 1226 patients was gath-
ered by 258 clinicians from specialized hypertension units rep-
resentative of the national distribution in Spain. The following
data were collected: Sociodemographic and anthropometric
data, hypertension risk factors, concurrent diseases, pharmaco-
logical treatment, and the SATMED-Q (Treatment Satisfaction),
MOS SF-12 (HRQoL) and Morisky-Green (Adherence) ques-
tionnaires. Reliability and validity were determined. Factor
analysis was used to check the instrument original structure.
RESULTS: The original 6 factor solution explained 87.3% of the
available variance; it was well deﬁned, with 6 eigenvalues above
1, simple factor loadings above 0.89, and communalities above
0.82. Correlations between dimensions varied between 0.07 and
0.51, being the dimension of undesired medicine effects the less
related. Dimensional Cronbach’s á ranged between 0.898 and
0.946. The one-dimensional Intraclass Correlation Coefﬁcient
attained a value of 0.903 (0.894–0.911, 95% CI) and Guttman
two-half index was 0.942. Treatment Satisfaction correlations
with HRQoL were lower (r from −0.005 to 0.240) than with
adherence (r from −0.154 to −0.314). Patients with controlled
BP levels (<140/90 mmHg) showed better treatment satisfaction,
HRQoL, and adherence (p < 0.001) than those not controlled.
CONCLUSIONS: The psychometric properties of the SATMED-
Q were very good in this chronic hypertensive population. Treat-
ment satisfaction measures are more sensitive to BP control
status than HRQoL measures. Patients following an effective 
and tolerated treatment show better satisfaction and better
adherence.
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OBJECTIVES: Intra-ocular pressure (IOP) ﬂuctuation over 24
hours is an independent risk factor for glaucoma progression.
Night time IOP measurement is not a routine practice, however.
The aim of this study was to predict the chance of a nocturnal
IOP peak °Y´ 18 mmHg from measurements made during the day.
METHODS: Daytime IOP measurements obtained from three
clinical trials were pooled. The night time IOP peak was deﬁned
as the maximum value between 0:00h and 04:00h. IOP mea-
surements at 08:00h, 12:00h, 16:00h, and 20:00h were
dichotomized, using the 18 mmHg threshold reported by the
Advanced Glaucoma Intervention Study. Patient IOPs were
assessed during the pre-treatment washout period and during
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treatment with either latanoprost or travoprost. A Bayesian
network was constructed to study the association between
daytime IOP and nocturnal IOP and treatment effects, adjusted
for trial effects. RESULTS: A total of 382 daily IOP vectors were
identiﬁed (pre-treatment: 208; latanoprost: 73; travoprost: 101).
IOP at 08:00h was associated with IOP at 12:00h, which was
associated with IOP at 16:00h. IOP at 20:00h was predicted by
IOPs at 12:00h and 16:00h. The predicted nocturnal peak IOP
was associated with IOPs at 12:00h and 20:00h. Travoprost con-
trolled the latter IOPs (12:00h and 20:00h) better than
latanoprost, increasing the probability of controlling nocturnal
IOP peaks °Y´ 18 mmHg (travoprost 76.9–77.5% versus
latanoprost 66.7–67.9%). Untreated patients with a diagnosis of
ocular hypertension had a high probability of developing a noc-
turnal IOP peak °Y´ 18 mmHg (92.1%). CONCLUSIONS:
Daytime IOP measurements are highly intercorrelated. IOPs at
12:00h and 20:00h were associated with the nocturnal IOP peak.
Bayesian networks can estimate the risk of a night time IOP peak
°Y´ 18 mmHg. Daytime IOP control is important for nocturnal
IOP control.
PEY2
EFFECTIVENESS OF TRAVOPROST VERSUS DORZOLAMIDE +
TIMOLOL FIXED COMBINATION IN FIRST LINE TREATMENT
OF GLAUCOMA:ANALYZED FROM THE UK GENERAL
PRACTITIONER RESEARCH DATABASE
Berdeaux G1, Lafuma A2, Guelfucci F3
1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine,
France, 3Cemka-Eval, Bourg-la-Reine, France
OBJECTIVE: To compare the effectiveness of travoprost 
(Travatan®) and a dorzolamide+timolol ﬁxed combination
(Cosopt®) as alternative ﬁrst line therapies for glaucoma using
data from the UK General Practitioner Research Database (UK-
GPRD). METHODS: Files of patients with ocular hypertension
or glaucoma, treated topically, or by surgery or laser therapy,
were extracted from the UK-GPRD. Patients starting ﬁrst line
treatment with travoprost, or the ﬁxed dorzolamide+timolol
combination, were selected. Treatment failure was deﬁned as a
prescription change (adding or removing a topical treatment).
Time to treatment failure was compared between treatments by
an adjusted Cox model. Propensity scores were used. RESULTS:
Files on 56,612 patients were extracted of which 39,808 had at
least one topical prescription for glaucoma. In total, 639 patients
were treated with travoprost, and 387 with dorzolamide+
timolol, as ﬁrst line therapies. Demographic and health charac-
teristics did not differ signiﬁcantly between patient groups.
Overall mean age at diagnosis was 70.0 years and 48.5% were
male. Treatment failure at one year occurred in 30.4% of
patients on travoprost and by 49.4% on dorzolamide+timolol (p
< 0.001). The hazard ratio for failure was lower with travoprost
(0.79: p < 0.03) after adjusting for age, gender, comorbidities and
duration of follow-up. CONCLUSION: According to UK-GPRD
information, travoprost appears to be more efﬁcient than dor-
zolamide+timolol as ﬁrst line therapy for glaucoma patients.
Patients continue longer with travoprost as ﬁrst line therapy.
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OBJECTIVE: To compare the efﬁcacy of latanoprost, bimato-
prost and travoprost for controlling IOP. METHODS: Ran-
domized trials were identiﬁed on Medline and Embase using the
following key words: glaucoma, ocular hypertension (OHT),
randomization, trial, latanoprost, bimatoprost and travoprost.
The studies had to compare at least two prostaglandins in
monotherapy. Cross-over experimental designs were excluded.
IOP at baseline and ﬁnal visit, age, gender, race and period of
follow-up were collected. Main outcome measure was IOP at
ﬁnal visit. Statistical analyses included random effects pooled
estimates of treatment effects, tests for publication bias, and
random-effects models to obtain adjusted treatment effects on
ﬁnal IOP after controlling for baseline IOP, and duration of
follow-up. We also estimated the number of responders (IOP <
18 mmHg) based on mean IOP value, standard deviation, and
sample size. Random effects Poisson regression models were used
to estimate the adjusted effects of treatments on response rates.
RESULTS: A total of 224 papers were identiﬁed, including 15
randomized clinical trials. Nine studies were used in the analy-
sis. Patient age varied from 56.7 to 68.8 years and baseline IOP
ranged from 22.3 to 26.5 mmHg. At total of 378 patients 
were treated with bimatoprost, 385 with travoprost and 555
with latanoprost. Patients treated with travoprost and bimato-
prost tended to have similarly lower IOP levels at the end of
follow-up (−0.98 mmHg [95% CI: −2.08;0.13] and −1.04 mmHg
[95% CI: −2.11;0.04], respectively) than those treated with
latanoprost. The combined effect of newer prostaglandin ana-
logues (bimatoprost/travoprost) was an adjusted decrease of
1.00 mmHg [95% CI: −1.91;−0.10], or a 17% higher adjusted
response rate (Incidence Rate Ratio 1.17, 95% CI, 1.00–1.35, p
= 0.04), compared to latanoprost. CONCLUSION: Travoprost
and bimatoprost may have greater efﬁcacy in controlling IOP for
patients with OHT or glaucoma.
PEY4
EFFECTIVENESS OF BRIMONIDINE VERSUS BRINZOLAMIDE
IN TREATMENT OF GLAUCOMA: AN ANALYSIS CONDUCTED
ON THE UNITED-KINGDOM GENERAL PRACTITIONER
RESEARCH DATABASE
Berdeaux G1, Lafuma A2, Guelfucci F3
1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine,
France, 3Cemka-Eval, Bourg-la-Reine, France
OBJECTIVE: To compare the effectiveness of brinzolamide
(Azopt®) and brimonidine (Alphagan®) in the treatment of
glaucoma according to the data collected in the United-Kingdom
General Practitioner Research Database (UK-GPRD).
METHODS: Files with a diagnosis of ocular hypertension, or
glaucoma, or treated with a topical treatment surgery or laser
were extracted. Patients with prescription for brimonidine or
dorzolamide mono-therapy were selected regardless of treatment
line (initial, second line, third, etc.). Treatment failure was
deﬁned as a prescription change (adding or removing a topical
treatment). Time to treatment failure was compared using an
adjusted Cox model. Adjustment for confounding factors used
the propensity score method. RESULTS: A total of 56,612
patients were extracted and 39,808 patients had at least one
topical prescription for glaucoma. A total of 2175 were treated
with brimonidine and 482 with brinzolamide monotherapy. No
signiﬁcant difference in the characteristics of the patients was
found. Patients were 69.5 years old on average at diagnosis and
46.5% were male. At one year, 54.4% of the brimonidine
patients had a treatment failure versus 42.3% with brinzolamide
(P < 0.001). The hazard ratio for a failure was 0.798 (P < 0.001)
lower with brinzolamide, after adjusting for age, gender, and
comorbidities. CONCLUSION: According to the UK-GPRD
